UY38435A - Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) - Google Patents
Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)Info
- Publication number
- UY38435A UY38435A UY0001038435A UY38435A UY38435A UY 38435 A UY38435 A UY 38435A UY 0001038435 A UY0001038435 A UY 0001038435A UY 38435 A UY38435 A UY 38435A UY 38435 A UY38435 A UY 38435A
- Authority
- UY
- Uruguay
- Prior art keywords
- hbv
- virus
- hepatitis
- pirazinas
- dihidro
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000010076 replication Effects 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere, en general, a nuevos agentes antivíricos. Específicamente, la presente invención se refiere a compuestos que pueden inhibir la proteína o proteínas codificada(s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, a composiciones que comprenden dichos compuestos, a métodos para inhibir la replicación del virus VHB, a métodos para tratar o prevenir la infección por VHB y a procesos e intermedios para la fabricación de los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000879 | 2018-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38435A true UY38435A (es) | 2020-05-29 |
Family
ID=64362288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038435A UY38435A (es) | 2018-11-02 | 2019-10-31 | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220009931A1 (es) |
| EP (1) | EP3873907A1 (es) |
| JP (1) | JP2022508042A (es) |
| KR (1) | KR20210098983A (es) |
| CN (1) | CN112969704A (es) |
| AR (1) | AR116948A1 (es) |
| AU (1) | AU2019373678A1 (es) |
| CA (1) | CA3118382A1 (es) |
| EA (1) | EA202191218A1 (es) |
| IL (1) | IL282648A (es) |
| SG (1) | SG11202104114TA (es) |
| TW (1) | TW202031660A (es) |
| UY (1) | UY38435A (es) |
| WO (1) | WO2020089456A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38437A (es) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
| AR117189A1 (es) * | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| ATE354942T1 (de) | 1999-04-23 | 2006-03-15 | Extenday Ip Ltd | Foliebefestigungs- und verankerungsteil |
| AU3009801A (en) | 1999-12-22 | 2001-07-03 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| JP5508400B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| WO2010024258A1 (ja) * | 2008-08-29 | 2010-03-04 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体 |
| US9399619B2 (en) | 2011-07-01 | 2016-07-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection |
| CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| AU2013207205B2 (en) | 2012-01-06 | 2017-02-02 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B |
| SG11201501362PA (en) | 2012-08-28 | 2015-03-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MY174042A (en) | 2012-08-28 | 2020-03-05 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b. |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| TW201446768A (zh) | 2013-03-15 | 2014-12-16 | Biogen Idec Inc | S1p及/或atx調節劑 |
| JP6533217B2 (ja) | 2013-05-17 | 2019-06-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類 |
| PL2997019T3 (pl) | 2013-05-17 | 2019-03-29 | Janssen Sciences Ireland Uc | Pochodne sulfamoilotiofenamidu i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2015057945A1 (en) | 2013-10-18 | 2015-04-23 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
| JP6490686B2 (ja) | 2013-11-14 | 2019-03-27 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゼパン誘導体及びｂ型肝炎感染の治療方法 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| KR101933844B1 (ko) | 2014-03-07 | 2018-12-28 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-융합된 헤테로아릴다이하이드로피리미딘 |
| US10183936B2 (en) | 2014-03-13 | 2019-01-22 | Indiana University Research And Technology Corporation | Hepatitis B core protein allosteric modulators |
| SG11201605896WA (en) | 2014-03-28 | 2016-08-30 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and their application in pharmaceuticals |
| WO2015172128A1 (en) | 2014-05-09 | 2015-11-12 | Indiana University Research And Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| CA2952541C (en) | 2014-08-14 | 2019-10-01 | F. Hoffmann-La Roche Ag | Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CN107406378A (zh) | 2014-12-02 | 2017-11-28 | 诺维拉治疗公司 | 用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物 |
| MX2017008720A (es) | 2014-12-30 | 2018-01-25 | Novira Therapeutics Inc | Derivados y metodos para tratamiento de las infecciones por hepatitis b. |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| AU2016232353B2 (en) | 2015-03-16 | 2019-05-16 | F. Hoffmann-La Roche Ag | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3292120B1 (en) | 2015-05-04 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3325477B1 (en) | 2015-07-21 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TWI730985B (zh) | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| US10253030B2 (en) | 2015-11-04 | 2019-04-09 | Qilu Pharmaceutical Co., Ltd. | Crystal form, preparation method and intermediate of dihydropyrido ring compound |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MY198617A (en) | 2016-03-07 | 2023-09-11 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| WO2017198744A1 (en) | 2016-05-20 | 2017-11-23 | F. Hoffmann-La Roche Ag | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| JP6935433B2 (ja) * | 2016-06-29 | 2021-09-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | ジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用 |
| JP7034133B2 (ja) | 2016-07-14 | 2022-03-11 | エフ．ホフマン－ラ ロシュ アーゲー | 感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物 |
| CN109476668B (zh) | 2016-07-14 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物 |
| WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018052967A1 (en) | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| CN110621672A (zh) | 2017-03-02 | 2019-12-27 | 组装生物科学股份有限公司 | 环状磺酰胺化合物及其使用方法 |
| CA3056886A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
-
2019
- 2019-10-31 UY UY0001038435A patent/UY38435A/es not_active Application Discontinuation
- 2019-10-31 AR ARP190103181A patent/AR116948A1/es unknown
- 2019-11-01 AU AU2019373678A patent/AU2019373678A1/en not_active Abandoned
- 2019-11-01 SG SG11202104114TA patent/SG11202104114TA/en unknown
- 2019-11-01 EA EA202191218A patent/EA202191218A1/ru unknown
- 2019-11-01 JP JP2021523650A patent/JP2022508042A/ja active Pending
- 2019-11-01 CA CA3118382A patent/CA3118382A1/en not_active Abandoned
- 2019-11-01 US US17/290,541 patent/US20220009931A1/en not_active Abandoned
- 2019-11-01 TW TW108139832A patent/TW202031660A/zh unknown
- 2019-11-01 EP EP19795566.9A patent/EP3873907A1/en not_active Withdrawn
- 2019-11-01 KR KR1020217016294A patent/KR20210098983A/ko not_active Application Discontinuation
- 2019-11-01 WO PCT/EP2019/079970 patent/WO2020089456A1/en unknown
- 2019-11-01 CN CN201980072925.8A patent/CN112969704A/zh active Pending
-
2021
- 2021-04-26 IL IL282648A patent/IL282648A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022508042A (ja) | 2022-01-19 |
| WO2020089456A1 (en) | 2020-05-07 |
| CA3118382A1 (en) | 2020-05-07 |
| AR116948A1 (es) | 2021-06-30 |
| TW202031660A (zh) | 2020-09-01 |
| KR20210098983A (ko) | 2021-08-11 |
| AU2019373678A1 (en) | 2021-05-27 |
| IL282648A (en) | 2021-06-30 |
| SG11202104114TA (en) | 2021-05-28 |
| CN112969704A (zh) | 2021-06-15 |
| EP3873907A1 (en) | 2021-09-08 |
| US20220009931A1 (en) | 2022-01-13 |
| EA202191218A1 (ru) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20029569A (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolo piperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb) | |
| ECSP20029558A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb) | |
| UY38434A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) | |
| ECSP21031082A (es) | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) | |
| UY38436A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
| CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
| ECSP21079317A (es) | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| UY38435A (es) | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
| ECSP21078893A (es) | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) | |
| ECSP21080338A (es) | Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb) | |
| UY38439A (es) | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) | |
| UY38681A (es) | Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| PH12021550978A1 (en) | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) | |
| EA202192969A1 (ru) | Новые оксалилпиперазины, активные против вируса гепатита b (вгв) | |
| EA202192967A1 (ru) | Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
| EA202192968A1 (ru) | Новые фенил- и пиридилмочевины, активные против вируса гепатита b (вгв) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20240610 |